TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03650257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp96
Description: 25 mcg IH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).
Study: NCT03650257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 23 days , 28 days for a a cycle, a total of 6 cycles ).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: Stupp regimen of radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Stupp regimen of radiotherapy
Study: NCT01551160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A communication and team-working intervention
Description: Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
Study: NCT02652273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept 125mg/ml
Study: NCT02832154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete online PA program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00913120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: injection
Study: NCT02699983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Use SparkPeople web-based program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Use Fitbit monitor and SparkPeople web-based program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Monitoring Device
Description: Wear Fitbit activity monitoring device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitoring Device
Description: Wear Fitbit activity monitoring device
Study: NCT04457167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted
Description: robot-assisted surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Not robot-assisted surgery
Description: Not robot-assisted surgery
Study: NCT00887432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03658668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: tDCS is a therapeutic treatment that utilizes low amplitude direct currents (\<4 mA) to induce changes in cortical excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Description: 20 minutes of cycling on an ergonomic cross-trainer

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Activity (PA)
Description: 20 minutes of cycling on an ergonomic cross-trainer
Study: NCT03800459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family empowerment program
Description: The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
Study: NCT00108147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circuit Training

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Rehabilitation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility and toning
Study: NCT00756470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 500 mg/m\^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m\^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
Study: NCT02418273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: These subjects will receive two doses of denosumab.
Study: NCT01008215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: Warfarin Dosing algorithm (paper and electronic version)
Study: NCT01718782

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask Ambu AuraOnce
Description: airway management and mechanical ventilation with laryngeal mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask LMA Supreme
Description: airway management and mechanical ventilation with laryngeal mask
Study: NCT04317703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin tartrate sesquihydrate and metformin
Description: Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release
Description: Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base).
Study: NCT04316208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP variations
Description: Patients will be ventilated with a PEEP of 5 cmH2O during induction of anesthesia. After craniotomy, the PEEP will be reduced to 0 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Next, PEEP will be increased to 5 cmH2O for 5 minutes and data will be collected at the end of 5 minutes. Finally, PEEP will be increased to 10 cmH2O for 5 minutes and data will be collected at the end of 5 minutes.
Study: NCT01684267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Gait Rehabilitation (RGR) Trainer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Gait Rehabilitation (RGR) Trainer
Study: NCT02871310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AS-118
Description: 1 tablet in the morning

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet in the morning
Study: NCT00302419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intracoronary infusion,
Description: streptokinase, 250,000 units

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary percutaneous coronary angioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary percutaneous coronary angioplasty
Study: NCT03130010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam or saline
Description: One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nefopam or saline
Description: One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
Study: NCT01284660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: DHA ingested orally by heavy smokers

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral ingestion of 5 placebo tablets
Description: Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
Study: NCT02123433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal conjugate 13 valent vaccine
Description: Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm.
Study: NCT00998426

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose monitoring before and after HepaGam B administration
Description: Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HepaGam B (Hepatitis B Immune Globulin (HBIG))
Description: Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
Study: NCT04101604

Intervention type: OTHER
Intervention: Collection of blood samples
Description: Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.

Intervention type: OTHER
Intervention: Collection of blood samples
Description: Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
Study: NCT03118674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harvoni
Description: One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
Study: NCT02388646

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brace Only
Description: This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bracing + Exercises
Description: This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
Study: NCT01661478

Intervention type: OTHER
Intervention: Training on motivational interviewing

Intervention type: OTHER
Intervention: Training on motivational interviewing
Study: NCT02682641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBRUTINIB
Description: Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
Study: NCT03285178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1701
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1701
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1701
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1701
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT00502827

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cell Phone Intervention
Description: Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.

Intervention type: OTHER
Group type: OTHER
Intervention: Recommended Standard of Care
Description: Advice from your physician to stop smoking and written materials designed to help you quit smoking.

Intervention type: OTHER
Group type: OTHER
Intervention: Recommended Standard of Care
Description: Advice from your physician to stop smoking and written materials designed to help you quit smoking.
Study: NCT01340820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AERAS-422
Description: rBCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AERAS-422
Description: rBCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Tice
Description: 1-8 x 10\^5 CFU
Study: NCT04452396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of continuous glucose monitoring
Description: Patients will wear a CGM device whilst undergoing diagnostic testing for reactive/spontaneous hypoglycaemia and then optimisation of anti-hypoglycaemic medication.
Study: NCT01642173

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography (C7 XR Dragonfly )
Description: Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.

Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography (C7 XR Dragonfly )
Description: Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
Study: NCT00824811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Eye Drops (Restasis)
Description: One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubricant Eye Drops (Refresh Endura™)
Description: One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone Eye Drops (FML Forte®)
Description: Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone Eye Drops (FML Forte®)
Description: Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®.
Study: NCT03881553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEATCAP
Description: NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEATCAP
Description: NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEATCAP
Description: NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SVS mattress
Description: SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SVS mattress
Description: SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SVS mattress
Description: SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
Study: NCT04105309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intentions
Description: Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intentions
Description: Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency Training
Description: Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messages
Description: SMS reminders sent to phone of implementation intentions 16 times throughout the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal Intentions
Description: Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)